Lyra Therapeutics Inc (LYRA): Narxning daromadga nisbati

Lyra Therapeutics Inc (LYRA) brendining ramzi va logotipi

Lyra Therapeutics, Inc. (LYRA) LOR a'zolari uchun dori yetkazib berish tizimlarini ishlab chiqadi, garchi u hozirda muvaffaqiyatsiz sinovlardan keyin kapital yetishmovchiligi bilan kurashayotgan bo'lsa-da. Kompaniyaning harakatlanuvchi P/S koeffitsiyenti bozor talabini baholashga yordam beradi, 1.40 esa ushbu parametrning joriy holatini belgilaydi. O'sish istiqbollari LYR-210 dorisining muvaffaqiyatiga va sinuslarni davolash bozoriga kengayish uchun uning FDA tomonidan tasdiqlanishi ehtimoliga bog'liq.

LYRA lyratherapeutics.com Narxning daromadga nisbati (04.07.2022 - 28.03.2026)

Lyra Therapeutics, Inc. (LYRA) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Kompaniyaning jamlanma tahliliyoti:Lyra Therapeutics
Lyra Therapeutics Inc brend mahsuloti

Biotehnologiya startapi Lyra Therapeutics, Inc. (LYRA) uchun P/S koeffitsiyenti kelgusidagi daromad oqimlariga nisbatan bozor kutganlarini ko'rsatuvchi indikator vazifasini o'taydi. Ushbu metrika joriy bozor kapitalizatsiyasining umumiy yillik savdolarga nisbatiga qarab hisoblanadi. P/S qiymatlarining tarixini tahlil qilish tijorat mahsuloti mavjud bo'lmagan holda aktivlarning haddan tashqari qimmat baholanganini aniqlash imkonini beradi. Muvaffaqiyatsiz klinik sinovlar va restrukturizatsiya sharoitida, ushbu ko'rsatkich qisqartirilgan operatsiyalar fonida aksiyalar narxining spekulyativ tabiatini yaqqol namoyon etadi.

Raqobatdosh kompaniyalar

HLN (Haleon) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Kenvue Inc KVUE|Verona Pharma Corp - Narxning daromadga nisbati|MENS: Kapitalizatsiyaning daromadga nisbati|Narx/daromad koeffitsiyenti Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Narxning daromadga nisbati|Perrigo Company PLC - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati alvotech.com|P/S multiplikatori Liquidia Technologies|Narxning daromadga nisbati Galapagos Genomics (GLPG)|ANIP: Narxning sotuvga nisbati|P/S multiplikatori MNKD (MannKind Corp)|Narx/daromad koeffitsiyenti Amphastar (AMPH)|PCRX: Kapitalizatsiyaning daromadga nisbati|SPRY - P/S multiplikatori|Theravance Biopharma, Inc. (TBPH) - Narxning daromadga nisbati|AQST (Aquestive Therapeutics) - Narxning daromadga nisbati|SCPH (scpharmaceuticals.com) - P/S multiplikatori|TECX: Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori EPRX (Eupraxia Pharmaceuticals)|Bozor kapitallashuvining daromadga nisbati BHST|Invizyne Technologies - P/S multiplikatori|oramed.com (ORMP) - Kapitalizatsiyaning daromadga nisbati|ENTX (enterabio.com) - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiya va daromad nisbati HYFT|ABVC (ABVC BioPharma, Inc) - P/S multiplikatori|P/S multiplikatori cumberlandpharma.com|Narxning daromadga nisbati Quantum BioPharma (QNTM)|FibroGen (FGEN) - Narx/daromad multiplikatori|P/S multiplikatori TELO (telomirpharma.com)|RANI - Kapitalizatsiyaning daromadga nisbati|SNYR - Narxning daromadga nisbati|rallybio.com - Kapitalizatsiyaning sotish hajmiga nisbati|LEXX: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Pulmatrix Inc|PTHL (Pheton Holdings) - P/S multiplikatori|Sotuvga nisbatan narx Aptorum Group Limited APM|P/S multiplikatori IBO|Kapitalizatsiyaning sotish hajmiga nisbati TNFA|cbdMD, Inc. - Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati PRFX|Altamira Therapeutics Ltd. - P/S multiplikatori|LIPO: Narxning daromadga nisbati|OPTN: P/S multiplikatori|Narxning sotuvga nisbati PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S multiplikatori|PTPI (Petros Pharmaceuticals Inc) - Kapitalizatsiyaning sotish hajmiga nisbati|P/S multiplikatori QLI|SLRN - Sotuvga nisbatan narx|P/S multiplikatori TFFP (TFF Pharmaceuticals, Inc)